Skip to main content
AmigoFish

Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

From BioSpace · · 21 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

Back to BioSpace · Report a problem